No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BHVN Biohaven
- 39.610
- +1.280+3.34%
Close Apr 23 16:00 ET
- 40.000
- +0.390+0.98%
Pre 07:14 ET
3.46BMarket Cap-6912P/E (TTM)
41.880High39.250Low2.09MVolume40.540Open38.330Pre Close83.75MTurnover2.91%Turnover RatioLossP/E (Static)87.42MShares62.21052wk High8.09P/B2.84BFloat Cap12.96052wk Low--Dividend TTM71.68MShs Float152.560Historical High--Div YieldTTM6.86%Amplitude7.100Historical Low40.127Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Biohaven Is Maintained at Buy by UBS
Biohaven Is Maintained at Buy by UBS
Biohaven Shares Rise After Closing of Public Offering, Disclosure of Stock Purchase by CEO
Biohaven (BHVN) shares rose 6.3% in recent Tuesday trading after the company announced the closing of its underwritten public offering and disclosed Chief Executive Vlad Coric's purchase of company sh
Director Gregory Bailey Acquires 48,780 Shares of Biohaven Ltd (BHVN)
Express News | Biohaven Ltd : UBS Raises Target Price to $60 From $59
Biohaven Insider Bought Shares Worth $4,999,991, According to a Recent SEC Filing
Vlad Coric, Director, Chief Executive Officer, on April 22, 2024, executed a purchase for 121,951 shares in Biohaven (BHVN) for $4,999,991. Following the Form 4 filing with the SEC, Coric has control
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Becton Dickinson (BDX)
Comments
This is why I love biotech
it's number 4, $Amylyx Pharmaceuticals(AMLX.US$ all time low 6.5 USD... hope you can grow and get all FDA approval... it's profitable already...
no 1. $Biogen(BIIB.US$ all time low 2 USD
no 2. $Neurocrine Biosciences(NBIX.US$ all time low 1.9 USD
no 3. $Biohaven(BHVN.US$ all time low 7 USD
no5. $argenx SE(ARGX.US$ all time low 17 USD
And it's not bubble. Of course there are also, biotech companies which are failed. But I think if it's growing into a right directio...
no 1. $Biogen(BIIB.US$ all time low 2 USD
no 2. $Neurocrine Biosciences(NBIX.US$ all time low 1.9 USD
no 3. $Biohaven(BHVN.US$ all time low 7 USD
no5. $argenx SE(ARGX.US$ all time low 17 USD
And it's not bubble. Of course there are also, biotech companies which are failed. But I think if it's growing into a right directio...
2
$Biohaven(BHVN.US$ buying at bid at 43ish over valued
ColumnsStaying Positive in Obesity Market After Setbacks: What's Next for Pfizer's Future?
Compared to the success of $Eli Lilly and Co(LLY.US$ and $NOVO NORDISK A/S(NONOF.US$, $Pfizer(PFE.US$ had a rocky start in launching its weight-loss pill. Last December, Pfizer announced that it would discontinue the development of a twice-daily iteration of its weight loss medication danuglipron, due to its unacceptable side effect profile as revealed by a Phase 2b trial. Before that, Pfizer gave up an oral dr...
+3
11
$Biohaven(BHVN.US$
looks unstoppable
Kv7
Start q1 ph2/3 in epilepsy
Strat q1 ph2/3 in bipolar disorder
Start q1 ph2 in MDD
Start q2 p2/p3 in ge. epilepsy
They are after $Xenon Pharmaceuticals(XENE.US$
Ph2 data in OCS Q2
Start h2 ph2 in migrane TRPM3
Start q2 ph2 in MS TYK2
Ph1 data q1 in IgG
ADC Trop2 and more
looks unstoppable
Kv7
Start q1 ph2/3 in epilepsy
Strat q1 ph2/3 in bipolar disorder
Start q1 ph2 in MDD
Start q2 p2/p3 in ge. epilepsy
They are after $Xenon Pharmaceuticals(XENE.US$
Ph2 data in OCS Q2
Start h2 ph2 in migrane TRPM3
Start q2 ph2 in MS TYK2
Ph1 data q1 in IgG
ADC Trop2 and more
2
$Biohaven(BHVN.US$ easy short to 37
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg